

Robert J Kreitman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/67574/publications.pdf>

Version: 2024-02-01

201
papers

11,635
citations

25034

57
h-index

30922

102
g-index

203
all docs

203
docs citations

203
times ranked

6857
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. <i>Blood Reviews</i> , 2022, 51, 100888.	5.7	4
2	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.	17.0	51
3	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
4	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7036-7036.	1.6	0
5	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2812-2814.	1.3	8
6	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. <i>Journal of Clinical Medicine</i> , 2021, 10, 2800.	2.4	13
7	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	1.4	40
8	Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. <i>Blood Advances</i> , 2021, 5, 4807-4816.	5.2	13
9	Immunotoxins: From Design to Clinical Application. <i>Biomolecules</i> , 2021, 11, 1696.	4.0	6
10	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
11	Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2020, 153, 322-327.	0.7	12
12	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. <i>Oncologist</i> , 2020, 25, e170-e177.	3.7	15
13	Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. <i>Leukemia and Lymphoma</i> , 2020, 61, 3177-3187.	1.3	9
14	Development of Recombinant Immunotoxins for Hairy Cell Leukemia. <i>Biomolecules</i> , 2020, 10, 1140.	4.0	18
15	Treatment of hairy cell leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 1107-1117.	2.2	4
16	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 1527-1538.	1.6	58
17	Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1367-1376.	2.4	9
18	Expression of the muscle-associated gene MYF6 in hairy cell leukemia. <i>PLoS ONE</i> , 2020, 15, e0227586.	2.5	5

#	ARTICLE	IF	CITATIONS
19	In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees. <i>Leukemia</i> , 2020, 34, 1934-1938.	7.2	3
20	Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. <i>Antibody Therapeutics</i> , 2019, 2, 12-21.	1.9	2
21	Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity. <i>Biomedicines</i> , 2019, 7, 1.	3.2	28
22	Hairy cell leukemia: present and future directions. <i>Leukemia and Lymphoma</i> , 2019, 60, 2869-2879.	1.3	37
23	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 275-282.	1.5	20
24	Moxetumomab Pasudotox-Tdfr in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. <i>Blood</i> , 2019, 134, 2808-2808.	1.4	8
25	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. <i>Blood</i> , 2019, 134, 1536-1536.	1.4	1
26	Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia. , 2019, 23, E52-E59.		3
27	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7003-7003.	1.6	5
28	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfr.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7014-7014.	1.6	0
29	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. <i>Blood</i> , 2018, 131, 2331-2334.	1.4	64
30	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600E-Mutant Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 7-13.	1.6	630
31	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	7.2	184
32	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory <i>BRAF</i> V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018, 132, 391-391.	1.4	40
33	Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7004-7004.	1.6	1
34	Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7060-7060.	1.6	2
35	Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7061-7061.	1.6	2
36	The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases. <i>Blood</i> , 2018, 132, 4859-4859.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Update on hairy cell leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 205-215.	0.3	19
38	Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. <i>Cellular Immunology</i> , 2017, 313, 59-66.	3.0	21
39	BL22: A Milestone in Targeting CD22. <i>Milestones in Drug Therapy</i> , 2017, , 151-176.	0.1	0
40	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
41	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1620-1627.	1.4	57
42	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016, 22, 310-318.	7.0	48
43	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	1.4	25
44	Removing a hair of doubt about BRAF targeting. <i>Blood</i> , 2015, 125, 1199-1200.	1.4	1
45	Cladribine Analogues via O6-(Benzotriazolyl) Derivatives of Guanine Nucleosides. <i>Molecules</i> , 2015, 20, 18437-18463.	3.8	12
46	Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on <i>Pseudomonas</i> Exotoxin A. <i>Bioconjugate Chemistry</i> , 2015, 26, 1120-1128.	3.6	25
47	Immunoconjugates in the management of hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 236-245.	1.7	24
48	Characterization of CD22 expression in acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 964-969.	1.5	129
49	Impact of telomere length on survival in classic and variant hairy cell leukemia. <i>Leukemia Research</i> , 2015, 39, 1360-1366.	0.8	8
50	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. <i>Blood</i> , 2015, 126, 4161-4161.	1.4	3
51	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7079-7079.	1.6	1
52	Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model. <i>PLoS ONE</i> , 2014, 9, e110716.	2.5	13
53	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. <i>British Journal of Haematology</i> , 2014, 166, 729-738.	2.5	13
54	Recombinant Immunotoxins. <i>Cancer Drug Discovery and Development</i> , 2014, , 569-584.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Immunotoxins for leukemia. <i>Blood</i> , 2014, 123, 2470-2477.	1.4	102
56	High prevalence of MAP2K1 mutations in variant and IGHV4-34â€œexpressing hairy-cell leukemias. <i>Nature Genetics</i> , 2014, 46, 8-10.	21.4	236
57	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8571-8576.	7.1	104
58	The bruton tyrosine kinase inhibitor ibrutinib (<sc>PCI</sc>â€œ32765) blocks hairy cell leukaemia survival, proliferation and <sc>B</sc> cell receptor signalling: a new therapeutic approach. <i>British Journal of Haematology</i> , 2014, 166, 177-188.	2.5	65
59	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontâ€line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. <i>Cancer</i> , 2014, 120, 3311-3319.	4.1	144
60	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. <i>Leukemia Research</i> , 2014, 38, 1224-1229.	0.8	34
61	Hairy Cell Leukemiaâ€œNew Genes, New Targets. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 184-195.	2.3	20
62	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. <i>Science Translational Medicine</i> , 2013, 5, 208ra147.	12.4	198
63	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. <i>Leukemia Research</i> , 2013, 37, 401-409.	0.8	100
64	Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2013, 140, 813-818.	0.7	17
65	Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 6313-6321.	7.0	70
66	Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 6873-6881.	7.0	62
67	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. <i>Blood</i> , 2013, 122, 2871-2871.	1.4	4
68	The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-â€l depletion. <i>Haematologica</i> , 2012, 97, 771-779.	3.5	37
69	Both variant and IGHV4-34â€œexpressing hairy cell leukemia lack the BRAF V600E mutation. <i>Blood</i> , 2012, 119, 3330-3332.	1.4	202
70	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11782-11787.	7.1	145
71	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	1.6	287
72	Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 152-160.	7.0	19

#	ARTICLE	IF	CITATIONS
73	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-666.	2.5	24
74	Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. Blood, 2012, 120, 1802-1802.	1.4	5
75	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. Blood, 2012, 120, 2896-2896.	1.4	1
76	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. Journal of Clinical Oncology, 2012, 30, 2503-2503.	1.6	0
77	The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. Blood, 2012, 120, 2488-2488.	1.4	0
78	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-6.	2.5	17
79	Renal Excretion of Recombinant Immunotoxins Containing Pseudomonas Exotoxin. Bioconjugate Chemistry, 2011, 22, 736-740.	3.6	5
80	Immunotoxins with decreased immunogenicity and improved activity. Leukemia and Lymphoma, 2011, 52, 87-90.	1.3	20
81	Molecular variant of hairy cell leukemia with poor prognosis. Leukemia and Lymphoma, 2011, 52, 99-102.	1.3	24
82	Response of hairy cell leukemia to bendamustine. Leukemia and Lymphoma, 2011, 52, 1153-1156.	1.3	14
83	Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Clinical Cancer Research, 2011, 17, 6398-6405.	7.0	201
84	Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. Cancer Research, 2011, 71, 6300-6309.	0.9	119
85	Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood, 2011, 117, 4844-4851.	1.4	31
86	Synergistic targeting of leukemia with leukotoxin and chemotherapy. Leukemia Research, 2011, 35, 1438-1439.	0.8	0
87	Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry Part B - Clinical Cytometry, 2011, 80B, 83-90.	1.5	57
88	The improvement of an anti-CD22 immunotoxin. MAbs, 2011, 3, 479-486.	5.2	15
89	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 82-86.	1.3	23
90	Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia. American Journal of Clinical Pathology, 2011, 136, 625-630.	0.7	58

#	ARTICLE	IF	CITATIONS
91	Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5742-5747.	7.1	97
92	Thrombotic Microangiopathy with Targeted Cancer Agents. Clinical Cancer Research, 2011, 17, 5858-5866.	7.0	83
93	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood, 2011, 118, 1760-1760.	1.4	8
94	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 248-248.	1.4	37
95	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. Blood, 2011, 118, 2575-2575.	1.4	3
96	Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia. Blood, 2011, 118, 2856-2856.	1.4	0
97	Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,. Blood, 2011, 118, 3909-3909.	1.4	0
98	Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants. Blood, 2011, 118, 931-931.	1.4	0
99	Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. British Journal of Haematology, 2010, 148, 99-109.	2.5	23
100	Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. Clinical Cancer Research, 2010, 16, 1894-1903.	7.0	139
101	Approach to the patient after relapse of hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 32-37.	1.3	14
102	Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2009, 27, 2983-2990.	1.6	208
103	CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. Clinical Cancer Research, 2009, 15, 832-839.	7.0	107
104	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. Clinical Cancer Research, 2009, 15, 5274-5279.	7.0	209
105	Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies. BioDrugs, 2009, 23, 1-13.	4.6	85
106	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood, 2009, 113, 3792-3800.	1.4	174
107	VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood, 2009, 114, 4687-4695.	1.4	143
108	Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies. Current Pharmaceutical Design, 2009, 15, 2652-2664.	1.9	45

#	ARTICLE	IF	CITATIONS
109	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.. Blood, 2009, 114, 3442-3442.	1.4	1
110	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 839-839.	1.4	7
111	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. Blood, 2009, 114, 888-888.	1.4	7
112	PRAME expression in hairy cell leukemia. Leukemia Research, 2008, 32, 1400-1406.	0.8	5
113	Soluble CD22 as a tumor marker for hairy cell leukemia. Blood, 2008, 112, 2272-2277.	1.4	27
114	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. Clinical Cancer Research, 2007, 13, 5144-5149.	7.0	351
115	Immunotoxin Treatment of Cancer*. Annual Review of Medicine, 2007, 58, 221-237.	12.2	340
116	Editorial Board Focus â€œ February 2007. Expert Opinion on Biological Therapy, 2007, 7, 157-160.	3.1	0
117	Releasable PEGylation of Mesothelin Targeted Immunotoxin SS1P Achieves Single Dosage Complete Regression of a Human Carcinoma in Mice. Bioconjugate Chemistry, 2007, 18, 773-784.	3.6	40
118	Immunoglobulin light chain repertoire in hairy cell leukemia. Leukemia Research, 2007, 31, 1231-1236.	0.8	7
119	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. Blood, 2007, 110, 855-855.	1.4	1
120	Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).. Blood, 2007, 110, 865-865.	1.4	5
121	Immunotoxins for targeted cancer therapy. AAPS Journal, 2006, 8, E532-E551.	4.4	258
122	Immunotoxins in the Treatment of Refractory Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1137-1151.	2.2	20
123	BL22 and lymphoid malignancies. Best Practice and Research in Clinical Haematology, 2006, 19, 685-699.	1.7	16
124	Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2. Journal of Immunotherapy, 2006, 29, 208-214.	2.4	66
125	Somatic hypermutation and VH gene usage in hairy cell leukaemia. British Journal of Haematology, 2006, 133, 504-512.	2.5	35
126	Immunotoxin therapy of cancer. Nature Reviews Cancer, 2006, 6, 559-565.	28.4	475

#	ARTICLE	IF	CITATIONS
127	Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1100-1110.	4.2	16
128	Immunotoxins in the Treatment of Hematologic Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1301-1311.	2.1	75
129	Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction. <i>Clinical Cancer Research</i> , 2006, 12, 2804-2811.	7.0	33
130	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 594-602.	2.3	6
131	Characterization of the B Cell Epitopes Associated with a Truncated Form of <i>Pseudomonas</i> Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. <i>Journal of Immunology</i> , 2006, 177, 8822-8834.	0.8	104
132	In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin. <i>Journal of Biological Chemistry</i> , 2005, 280, 607-617.	3.4	96
133	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. <i>Clinical Cancer Research</i> , 2005, 11, 5840-5846.	7.0	65
134	Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 6719-6729.	1.6	262
135	HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. <i>Clinical Cancer Research</i> , 2005, 11, 1545-1550.	7.0	78
136	Recombinant immunotoxins for the treatment of haematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1115-1128.	3.1	17
137	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. <i>Protein Expression and Purification</i> , 2004, 33, 123-133.	1.3	46
138	Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. <i>Annals of Thoracic Surgery</i> , 2004, 78, 436-443.	1.3	8
139	Recombinant immunotoxins for treating cancer. <i>International Journal of Medical Microbiology</i> , 2004, 293, 577-582.	3.6	81
140	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. <i>Blood</i> , 2004, 103, 2718-2726.	1.4	64
141	BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma. <i>Blood</i> , 2004, 104, 4613-4613.	1.4	1
142	Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1691-2.	4.1	4
143	Immunotoxin therapy of hematologic malignancies. <i>Seminars in Oncology</i> , 2003, 30, 545-557.	2.2	46
144	Taming ricin toxin. <i>Nature Biotechnology</i> , 2003, 21, 372-374.	17.5	13

#	ARTICLE	IF	CITATIONS
145	Immunobiological treatments of hairy-cell leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 117-133.	1.7	20
146	Minimal Residual Disease Detection in Hairy Cell Leukemia. American Journal of Clinical Pathology, 2003, 119, 213-217.	0.7	66
147	Minimal Residual Disease Detection in Hairy Cell Leukemia Comparison of Flow Cytometric Immunophenotyping With Clonal Analysis Using Consensus Primer Polymerase Chain Reaction for the Heavy Chain Gene. American Journal of Clinical Pathology, 2003, 119, 213-217.	0.7	29
148	Immunotoxins. , 2003, , 391-433.		0
149	Recombinant toxins for the treatment of cancer. Current Opinion in Molecular Therapeutics, 2003, 5, 44-51.	2.8	42
150	Recombinant fusion toxins for cancer treatment. Expert Opinion on Biological Therapy, 2002, 2, 785-791.	3.1	9
151	Augmentation of the Activity of an Immunotoxin, Anti-Tac(Fv)-PE40KDEL, in T Cell Lines Infected with Human T Cell Leukemia Virus Type-I. Leukemia and Lymphoma, 2002, 43, 885-888.	1.3	12
152	Hairy Cell Leukemia. American Journal of Cancer, 2002, 1, 189-203.	0.4	0
153	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood, 2002, 99, 1320-1326.	1.4	41
154	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood, 2002, 99, 1320-6.	1.4	12
155	Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clinical Cancer Research, 2002, 8, 995-1002.	7.0	135
156	Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clinical Cancer Research, 2002, 8, 1004-13.	7.0	100
157	Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clinical Cancer Research, 2002, 8, 2345-55.	7.0	32
158	Monoclonal Antibodies in Cancer–Second International Congress. 29 August-1 September 2002, Banff, Canada. IDrugs: the Investigational Drugs Journal, 2002, 5, 1057-61.	0.7	0
159	Targeted therapies - First International Congress. IDrugs: the Investigational Drugs Journal, 2002, 5, 949-54.	0.7	0
160	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New England Journal of Medicine, 2001, 345, 241-247.	27.0	509
161	Antibody Response to DTâ€“GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyteâ€“Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Immunology, 2001, 100, 191-197.	3.2	44
162	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin. International Journal of Cancer, 2001, 92, 861-870.	5.1	22

#	ARTICLE	IF	CITATIONS
163	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1622-1636.	1.6	416
164	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. <i>Journal of Immunotherapy</i> , 2000, 23, 473-479.	2.4	60
165	Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. <i>International Journal of Cancer</i> , 2000, 87, 86-94.	5.1	70
166	Making Fusion Toxins to Target Leukemia and Lymphoma. , 2000, 25, 215-226.		7
167	Immunotoxins. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 1117-1129.	1.8	27
168	Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the β 2-Macroglobulin Receptor. <i>Journal of Biological Chemistry</i> , 2000, 275, 7566-7573.	3.4	41
169	Inhibition of TNF- β Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. <i>Journal of Immunology</i> , 2000, 165, 7150-7156.	0.8	59
170	Chimeric toxins in cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2000, 5, 61-71.	1.1	0
171	Development of Lymphoproliferative Disorder of Granular Lymphocytes in Association with Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 37, 97-104.	1.3	19
172	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. <i>Blood</i> , 1999, 94, 3340-3348.	1.4	161
173	Immunotoxins in cancer therapy. <i>Current Opinion in Immunology</i> , 1999, 11, 570-578.	5.5	200
174	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. <i>Nature Medicine</i> , 1999, 5, 817-822.	30.7	44
175	Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys. <i>Toxicology and Applied Pharmacology</i> , 1999, 158, 152-160.	2.8	29
176	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. <i>Leukemia Research</i> , 1999, 23, 527-538.	0.8	27
177	¹¹¹ Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33
178	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. , 1999, 81, 148-155.		81
179	An scFv phage clone that binds to human β 2-microglobulin. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1999, 4, 231-236.	2.4	2
180	High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials. <i>Protein Expression and Purification</i> , 1999, 16, 190-201.	1.3	34

#	ARTICLE	IF	CITATIONS
181	Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. <i>Hematology</i> , 1999, 4, 283-303.	1.5	1
182	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. , 1998, 51, 162-173.		12
183	Similarities in the Biodistribution of Iodine-Labeled Anti-Tac Single-Chain Disulfide-Stabilized Fv Fragment and Anti-Tac Disulfide-Stabilized Fv Fragment. <i>Nuclear Medicine and Biology</i> , 1998, 25, 387-393.	0.6	11
184	Cell-Specific Modulation of Drug Resistance in Acute Myeloid Leukemic Blasts by Diphtheria Fusion Toxin, DT388-GMCSF. <i>Bioconjugate Chemistry</i> , 1998, 9, 490-496.	3.6	26
185	Recombinant toxins in haematologic malignancies and solid tumours. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1405-1427.	4.1	0
186	An Early Step in Pseudomonas Exotoxin Action Is Removal of the Terminal Lysine Residue, Which Allows Binding to the KDEL Receptor. <i>Biochemistry</i> , 1997, 36, 14577-14582.	2.5	84
187	Interleukin-4 Receptor Expression on AIDS-Associated Kaposi's Sarcoma Cells and Their Targeting by a Chimeric Protein Comprised of Circularly Permuted Interleukin-4 and Pseudomonas Exotoxin. <i>Molecular Medicine</i> , 1997, 3, 327-338.	4.4	36
188	Recombinant Toxins Containing Human Granulocyte-Macrophage Colony-Stimulating Factor and Either Pseudomonas Exotoxin or Diphtheria Toxin Kill Gastrointestinal Cancer and Leukemia Cells. <i>Blood</i> , 1997, 90, 252-259.	1.4	72
189	Getting plant toxins to fuse. <i>Leukemia Research</i> , 1997, 21, 997-999.	0.8	28
190	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. <i>British Journal of Haematology</i> , 1997, 98, 952-959.	2.5	6
191	Targeting Pseudomonas exotoxin to hematologic malignancies. <i>Seminars in Cancer Biology</i> , 1995, 6, 297-306.	9.6	52
192	Circularly permuted interleukin 4 retains proliferative and binding activity. <i>Cytokine</i> , 1995, 7, 311-318.	3.2	16
193	Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. <i>International Journal of Cancer</i> , 1994, 57, 856-864.	5.1	25
194	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-TAC Fv fragment and truncated pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994, 58, 142-149.	5.1	44
195	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. <i>International Journal of Cancer</i> , 1994, 58, 574-581.	5.1	112
196	Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. <i>Biochemistry</i> , 1994, 33, 5451-5459.	2.5	134
197	Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity. <i>Biochemistry</i> , 1994, 33, 11637-11644.	2.5	16
198	Purification and characterization of IL6-PE4e, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. <i>Bioconjugate Chemistry</i> , 1993, 4, 581-585.	3.6	26

#	ARTICLE	IF	CITATIONS
199	Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. <i>Bioconjugate Chemistry</i> , 1993, 4, 112-120.	3.6	69
200	Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor .alpha. within Pseudomonas exotoxin as a targeting ligand. <i>Bioconjugate Chemistry</i> , 1992, 3, 58-62.	3.6	20
201	Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor .alpha. at different locations in Pseudomonas exotoxin. <i>Bioconjugate Chemistry</i> , 1992, 3, 63-68.	3.6	34